SMN1 and proximal spinal muscular atrophy: Particularly, plasma phosphorylated neurofilament heavy chain (pNF-H), SMN protein and serum creatinine levels have been proposed as promising biomarkers for disease activity and treatment response in SMA [6, 11, 25, 31, 32].